首页> 外文期刊>The Journal of Urology >Quantifying the Contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial
【24h】

Quantifying the Contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial

机译:量化症状改善对中度至重度良性前列腺增生男性满意度的贡献:CombAT试验的4年数据

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose: We quantified the magnitude of symptom improvement required to achieve different levels of patient reported satisfaction, as assessed by the Patient Perception of Study Medication questionnaire. Materials and Methods: This multicenter, international, double-blind, randomized study included men 50 years old or older with International Prostate Symptom Score 12 or greater, prostate volume 30 cc or greater, total prostate specific antigen 1.5 to 10.0 ng/ml, maximum urinary flow greater than 5 and less than or equal to 15 ml per second and minimum voided volume 125 ml or greater. Patients were randomized to dutasteride (0.5 mg) and/or tamsulosin (0.4 mg) but results are reported without respect to treatment. International Prostate Symptom Score and Patient Perception of Study Medication responses were assessed at baseline and at 3-month intervals for 48 months. Using pooled data Patient Perception of Study Medication responses were correlated with changes in International Prostate Symptom Score from baseline for 2 Patient Perception of Study Medication measures, including 1) total score and 2) overall satisfaction on question 11, "Overall how satisfied are you with the study medication and its effect on your urinary problems?" Results: Patient Perception of Study Medication total score and question 11 correlated significantly with the mean change in International Prostate Symptom Score from baseline (p <0.0001). A response of very satisfied to question 11 was associated with an International Prostate Symptom Score improvement of -9.4 points while a response of very dissatisfied was associated with 1.3-point worsening. There was only moderate correlation between Patient Perception of Study Medication question 11 and changes in symptoms (r = 0.38). Thus, factors other than lower urinary tract symptoms also contribute to satisfaction and they could not be formally analyzed in this report. Conclusions: We noted correlations between patient satisfaction and the magnitude of the International Prostate Symptom Score change from baseline, which allowed us to determine treatment outcomes in terms of true clinical instead of only statistical significance.
机译:目的:我们量化了达到不同水平的患者报告的满意程度所需的症状改善的程度,这是通过《研究药物的患者知觉》问卷进行评估的。材料和方法:这项多中心,国际,双盲,随机研究包括年龄在50岁或以上且国际前列腺症状评分为12或更高,前列腺体积为30 cc或更高,总前列腺特异性抗原为1.5至10.0 ng / ml的男性尿流大于5且小于或等于15毫升/秒,最小排尿量125毫升或更大。患者被随机分为度他雄胺(0.5 mg)和/或坦索罗辛(0.4 mg),但报告的结果与治疗无关。国际前列腺症状评分和患者对研究的感知在基线和每三个月间隔48个月评估药物反应。使用汇总的数据,对2种患者对研究药物的知觉度,患者对研究药物反应的知觉与基线水平国际前列腺症状评分的变化相关,包括1)总分和2)对问题11的总体满意度:研究药物及其对您泌尿系统疾病的影响?”结果:患者对研究药物总得分的感知和问题11与国际前列腺症状得分相对于基线的平均变化显着相关(p <0.0001)。对问题11的非常满意的回应与国际前列腺症状评分改善-9.4分相关,而对不满意的回应与1.3分恶化有关。患者对研究药物的看法中的问题11与症状的变化之间只有中等程度的相关性(r = 0.38)。因此,除下尿路症状外的其他因素也有助于满意度,因此本报告中无法对其进行正式分析。结论:我们注意到患者满意度和国际前列腺症状评分从基线变化的幅度之间的相关性,这使我们能够根据真实的临床而不是仅统计意义来确定治疗结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号